Quercetin increases the bioavailability of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in rats

Food and Chemical Toxicology

Volumn 46, Issue 11, 2008, Pages 3422-3428

  Schutte, Maaike E ^a,b   Alink, Gerrit M ^a   Freidig, Andreas P ^b   Spenkelink, Bert ^a   Vaessen, Judith C H ^a   van de Sandt, Johannes J M ^b   Groten, John P ^b,c   Rietjens, Ivonne M C M ^a,b  

^a WAGENINGEN UNIVERSITY   (Netherlands)

^b TNO   (Netherlands)

^c Food and Chemical Risk Analysis Department ^*  (Netherlands)

Author keywords

ABC transporters; Caco 2 monolayers; In silico modelling; PhIP; Quercetin; Rat

Indexed keywords

2 AMINO 1 METHYL 6 PHENYLIMIDAZO[4,5 B]PYRIDINE; QUERCETIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOAVAILABILITY; CELL STRAIN CACO 2; COMPUTER MODEL; CONTROLLED STUDY; DIETARY INTAKE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; RAT;

ANIMALS; ANTIOXIDANTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT, ACTIVE; CACO-2 CELLS; CARCINOGENS; HUMANS; IMIDAZOLES; MALE; MODELS, BIOLOGICAL; QUERCETIN; RANDOM ALLOCATION; RATS; RATS, WISTAR;

RATTUS;

EID: 54849441001     PISSN: 02786915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fct.2008.08.015     Document Type: Article

References (43)

1. Artursson P., and Karlsson J. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem. Biophys. Res. Commun. 175 (1991) 880-885
2. Augustsson K., Skog K., Jagerstad M., and Steineck G. Assessment of the human exposure to heterocyclic amines. Carcinogenesis 18 (1997) 1931-1935
3. Chan L.M.S., Lowes S., and Hirst B.H. The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. Eur. J. Pharm. Sci. 21 (2004) 25-51
4. Chen X., Yin O.Q.P., Zuo Z., and Chow M.S.S. Pharmacokinetics and modeling of quercetin and metabolites. Pharm. Res. 22 (2005) 892-901
5. Choi J.-S., Choi H.-K., and Shin S.-C. Enhanced bioavailability of paclitaxel after oral coadministration with flavone in rats. Int. J. Pharm. 275 (2004) 165-170
6. Choi J.-S., and Han H.-K. Enhanced oral exposure of diltiazem by the concomitant use of naringin in rats. Int. J. Pharm. 305 (2005) 122-128
7. Choi J.-S., and Han H.-K. Pharmacokinetic interaction between diltiazem and morin, a flavonoid, in rats. Pharmacol. Res. 52 (2005) 386-391
8. Choi J.S., Jo B.W., and Kim Y.C. Enhanced paclitaxel bioavailability after oral administration of paclitaxel or prodrug to rats pretreated with quercetin. Eur. J. Pharm. Biopharm. 57 (2004) 313-318
9. Crofts F.G., Sutter T.R., and Strickland P.T. Metabolism of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine by human cytochrome P4501A1, P4501A2 and P4501B1. Carcinogenesis 19 (1998) 1969-1973
10. Dietrich C.G., de Waart D.R., Ottenhoff R., Schoots I.G., and Elferink R.P.J. Increased bioavailability of the food-derived carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in MRP2-deficient rats. Mol. Pharmacol. 59 (2001) 974-980
11. Dietrich C.G., Geier A., and Oude Elferink R.P. ABC of oral bioavailability: transporters as gatekeepers in the gut. Gut 52 (2003) 1788-1795
12. Duizer E., Penninks A.H., Stenhuis W.H., and Groten J.P. Comparison of permeability characteristics of the human colonic Caco-2 and rat small intestinal IEC-18 cell lines. Journal of Controlled Releases 49 (1997) 39-49
13. Ebeler S.E., Dingley K.H., Ubick E., Abel S., Mitchell A.E., Burns S.A., Steinberg F.M., and Clifford A.J. Animal models and analytical approaches for understanding the relationships between wine and cancer. Drugs Exp. Clin. Res. 31 (2005) 19-27
14. Geleijnse J.M., Launer L.J., Van der Kuip D.A., Hofman A., and Witteman J.C. Inverse association of tea and flavonoid intakes with incident myocardial infarction: the Rotterdam study. Am. J. Clin. Nutr. 75 (2002) 880-886
15. Hertog M.G., Hollman P.C., Katan M.B., and Kromhout D. Intake of potentially anticarcinogenic flavonoids and their determinants in adults in The Netherlands. Nutr. Cancer 20 (1993) 21-29
16. Hirohashi T., Suzuki H., Chu X.Y., Tamai I., Tsuji A., and Sugiyama Y. Function and expression of multidrug resistance-associated protein family in human colon adenocarcinoma cells (Caco-2). J. Pharmacol. Exp. Ther. 292 (2000) 265-270
17. Hollman P.C., van Trijp J.M., Buysman M.N., van der Gaag M.S., Mengelers M.J., de Vries J.H., and Katan M.B. Relative bioavailability of the antioxidant flavonoid quercetin from various foods in man. FEBS Lett. 418 (1997) 152-156
18. Kitagawa S., Nabekura T., Takahashi T., Nakamura Y., Sakamoto H., Tano H., Hirai M., and Tsukahara G. Structure-activity relationships of the inhibitory effects of flavonoids on P-glycoprotein-mediated transport in KB-C2 cells. Biol. Pharm. Bull. 28 (2005) 2274-2278
19. Knekt P., Jarvinen R., Seppanen R., Hellovaara M., Teppo L., Pukkala E., and Aromaa A. Dietary flavonoids and the risk of lung cancer and other malignant neoplasms. Am. J. Epidemiol. 146 (1997) 223-230
20. Layton D.W., Bogen K.T., Knize M.G., Hatch F.T., Johnson V.M., and Felton J.S. Cancer risk of heterocyclic amines in cooked foods: an analysis and implications for research. Carcinogenesis 16 (1995) 39-52
21. Lee K., Klein-Szanto A.J., and Kruh G.D. Analysis of the MRP4 drug resistance profile in transfected NIH3T3 cells. J. Natl. Cancer Inst. 92 (2000) 1934-1940
22. Leslie E.M., Mao Q., Oleschuk C.J., Deeley R.G., and Cole S.P.C. Modulation of multidrug resistance protein 1 (MRP1/ABCC1) transport and ATPase activities by interaction with dietary flavonoids. Mol. Pharmacol. 59 (2001) 1171-1180
23. Mitchell D.B., Santone K.S., and Acosta D. Evaluation of cytotoxicity in cultured cells by enzyme leakage. J. Tissue Cult. Methods 6 (1980) 113-116
24. Nguyen H., Zhang S., and Morris M.E. Effect of flavonoids on MRP1-mediated transport in Panc-1 cells. J. Pharm. Sci. 92 (2003) 250-257
25. Prime-Chapman H.M., Fearn R.A., Cooper A.E., Moore V., and Hirst B.H. Differential multidrug resistance-associated protein 1 through 6 isoform expression and function in human intestinal epithelial Caco-2 cells. J. Pharmacol. Exp. Ther. 311 (2004) 476-484
26. Scheffer G.L., Kool M., de Haas M., de Vree J.M., Pijnenborg A.C., Bosman D.K., Elferink R.P., van der Valk P., Borst P., and Scheper R.J. Tissue distribution and induction of human multidrug resistant protein 3. Lab. Invest. 82 (2002) 193-201
27. Schut H.A., and Snyderwine E.G. DNA adducts of heterocyclic amine food mutagens: implications for mutagenesis and carcinogenesis. Carcinogenesis 20 (1999) 353-368
28. Schutte M.E., Freidig A.P., van de Sandt J.J.M., Alink G.M., Rietjens I.M.C.M., and Groten J.P. An in vitro and in silico study on the flavonoid-mediated modulation of the transport of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) through Caco-2 monolayers. Toxicol. Appl. Pharmacol. 217 (2006) 204-215
29. Schutte M.E., van de Sandt J.J.M., Alink G.M., Groten J.P., and Rietjens I.M.C.M. Myricetin stimulates the absorption of the pro-carcinogen PhIP. Cancer Lett. 231 (2006) 36-42
30. Sesink A.L.A., Arts I.C.W., de Boer V.C.J., Breedveld P., Schellens J.H.M., Hollman P.C.H., and Russel F.G.M. Breast cancer resistance protein (Bcrp1/Abcg2) limits net intestinal uptake of quercetin in rats by facilitating apical efflux of glucuronides. Mol. Pharmacol. 67 (2005) 1999-2006
31. Taipalensuu J., Tornblom H., Lindberg G., Einarsson C., Sjoqvist F., Melhus H., Garberg P., Sjostrom B., Lundgren B., and Artursson P. Correlation of gene expression of ten drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers. J. Pharmacol. Exp. Ther. 299 (2001) 164-170
32. Takano M., Yumoto R., and Murakami T. Expression and function of efflux drug transporters in the intestine. Pharmacol. Ther. 109 (2006) 137-161
33. Turesky R.J., LAng N.P., Butler M.A., Teitel C.H., and Kadlubar F.F. Metabolic activation of carcinogenic heterocyclic aromatic amines by human liver and colon. Carcinogenesis 12 (1991) 1839-1845
34. van Aubel R.A., Smeets P.H., Peters J.G., Bindels R.J., and Russel F.G. The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP. J. Am. Soc. Nephrol. 13 (2002) 595-603
35. van Herwaarden A.E., Jonker J.W., Wagenaar E., Brinkhuis R.F., Schellens J.H.M., Beijnen J.H., and Schinkel A.H. The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. Cancer Res. 63 (2003) 6447-6452
36. van Zanden J.J., Wortelboer H.M., Bijlsma S., Punt A., Usta M., Bladeren P.J., Rietjens I.M.C.M., and Cnubben N.H.P. Quantitative structure activity relationship studies on the flavonoid mediated inhibition of multidrug resistance proteins 1 and 2. Biochem. Pharmacol. 69 (2005) 699-708
37. Vitaglione P., and Fogliano V. Use of antioxidants to minimize the human health risk associated to mutagenic/carcinogenic heterocyclic amines in food. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 802 (2004) 189-199
38. Vlaming M.L.H., Mohrmann K., Wagenaar E., de Waart D.R., Oude Elferink R.P.J., Lagas J.S., van Tellingen O., Vainchtein L.D., Rosing H., Beijnen J.H., Schellens J.H.M., and Schinkel A.H. Carcinogen and anti-cancer drug transport by Mrp2 in vivo: studies using Mrp2 (Abcc2) knockout mice. J. Pharmacol. Exp. Ther. 318 (2006) 319-327
39. Walle U.K., and Walle T. Transport of the cooked-food mutagen 2-amino-1-methyl-6-phenylimidazo-[4,5-b ]pyridine (PhIP) across the human intestinal Caco-2 cell monolayer: role of efflux pumps. Carcinogenesis 20 (1999) 2153-2157
40. Wang X., and Morris M.E. Effects of the flavonoid chrysin on nitrofurantoin pharmacokinetics in rats: potential involvement of ABCG2. Drug Metab. Dispos. 35 (2007) 268-274
41. Wu C.-P., Calcagno A.M., Hladky S.B., Ambudkar S.V., and Barrand M.A. Modulatory effects of plant phenols on human multidrug-resistance proteins 1, 4 and 5 (ABCC1, 4 and 5). FEBS J. 272 (2005) 4725-4740
42. Zhang S., Wang X., Sagawa K., and Morris M.E. Flavonoids chrysin and benzoflavone, potent breast cancer resistance protein inhibitors, have no significant effect on topotecan pharmacokinetics in rats or mdr1a/1b (-/-) mice. Drug Metab. Dispos. 33 (2005) 341-348
43. Zimmermann C., Gutmann H., Hruz P., Gutzwiller J.P., Beglinger C., and Drewe J. Mapping of multidrug resistance gene 1 and multidrug resistance-associated protein isoform 1-5 mRNA expression along the human intestinal tract. Drug Metab. Dispos. 33 (2005) 219-224